NMRA

Neumora Therapeutics Inc

Sep 17 • 04:00PM ET

1.45

-0.05 -3.33 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX NBIX AXSM ACAD SAGE ALKS BHVN PRTA AVXL

| Held by: VTI VXF IBB SCHA VHT PRFZ SCHB BTEC MSSM IBBQ

Index	-	P/E	-	EPS (ttm)	-1.57	Insider Own	66.51%	Shs Outstand	161.95M	Perf Week	-11.04%
Market Cap	234.82M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	0.00%	Shs Float	54.24M	Perf Month	-11.59%
Enterprise Value	37.19M	PEG	-	EPS next Q	-0.33	Inst Own	22.97%	Short Float	9.65%	Perf Quarter	82.85%
Income	-252.09M	P/S	-	EPS this Y	7.62%	Inst Trans	-17.39%	Short Ratio	4.05	Perf Half Y	25.00%
Sales	0.00M	P/B	1.28	EPS next Y	28.56%	ROA	-80.25%	Short Interest	5.23M	Perf YTD	-86.32%
Book/sh	1.13	P/C	1.08	EPS next 5Y	14.93%	ROE	-89.37%	52W High	17.19 -91.56%	Perf Year	-87.95%
Cash/sh	1.34	P/FCF	-	EPS past 3/5Y	0.69% -	ROIC	-124.38%	52W Low	0.61 137.32%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.53% 6.07%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.84%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.54	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	36.91	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	10.54	EPS Q/Q	11.67%	SMA20	-12.12%	Beta	2.93	Target Price	7.00
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	-13.10%	Rel Volume	0.43	Prev Close	1.50
Employees	110	LT Debt/Eq	0.11	Earnings	Aug 06 AMC	SMA200	-39.30%	Avg Volume	1.29M	Price	1.45
IPO	Sep 15, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.99% -	Trades		Volume	550,375	Change	-3.33%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform	$1
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$29 → $4
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $15
Oct-01-24	Initiated	H.C. Wainwright	Buy	$30
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Show Previous Ratings

Sep-17-25 09:40AM	Apple initiated, Hershey upgraded: Wall Streets top analyst calls (TipRanks)
Sep-16-25 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
Sep-02-25 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in September (GlobeNewswire)
Aug-20-25 12:13AM	Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861 (Insider Monkey)
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive) -11.52%
04:05PM	Loading…
Aug-06-25 04:05PM	Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:23AM	Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating (Insider Monkey)
Jul-23-25 07:00AM	Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating (Insider Monkey)
Jul-09-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 (GlobeNewswire) +13.12%
May-13-25 03:10AM	Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ... (GuruFocus.com)
May-12-25 04:01PM	Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:00AM	Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-22-25 02:49AM	Former Neumora CEO to lead Galapagos spinout (BioPharma Dive) +6.82%
Apr-21-25 04:10PM	Galapagos Announces Executive Leadership Updates (GlobeNewswire)
05:45AM	Loading…
Mar-18-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Mar-07-25 12:26PM	J&J drops Phase III MDD programme due to lack of efficacy (Clinical Trials Arena)
07:08AM	J&J scraps depression testing for potential blockbuster drug (BioPharma Dive)
Mar-04-25 08:30AM	Neumora Therapeutics to Present at Leerink Global Healthcare Conference (GlobeNewswire)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Mar-03-25 07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.94%
Feb-28-25 05:45AM	Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-26-25 08:46PM	Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-18-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-13-25 10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:00AM	Neumora Therapeutics Announces Leadership Transition (GlobeNewswire)
Feb-11-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire) -6.18%
Jan-04-25 08:00AM	Neumora shares look oversold after 80% drop, says Mizuho (TipRanks)
Jan-03-25 07:20AM	Neumora Therapeutics navacaprant did not meet primary endpoint in depression (TipRanks) +10.15%
05:07PM	Loading…
Jan-02-25 05:07PM	Results are in for a new depression drug trial, and they're cratering this stock (Quartz) -81.42%
04:22PM	Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops (Investor's Business Daily)
01:28PM	Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial (Insider Monkey)
01:07PM	Neumora shares sink following Phase III flop in MDD (Pharmaceutical Technology)
12:00PM	Top Stock Movers Now: Uber, Unity Software, Tesla, and More (Investopedia)
10:47AM	Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals (Investopedia)
09:59AM	Stock in Biotech Neumora Plunges 80% as Depression Drug Fails (Barrons.com)
09:54AM	Neumora Plunges After Major Depression Drug Fails in Study (Bloomberg)
08:30AM	Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials (Benzinga)
07:00AM	Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder (GlobeNewswire)
Nov-19-24 08:53AM	Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-12-24 07:00AM	Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -17.08%
Nov-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) +6.72%
Oct-29-24 07:00AM	Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henry Gosebruch	Officer	Mar 12 '25	Proposed Sale	1.43	15,000	21,450		Mar 12 04:49 PM
BERNS PAUL L	See Remarks	Feb 18 '25	Sale	1.69	13,871	23,468	7,405,004	Feb 20 05:14 PM
Milligan Michael Lee	See Remarks	Feb 18 '25	Sale	1.69	1,978	3,351	22,470	Feb 20 05:14 PM
Aurora Daljit Singh	Chief Strategy Officer	Feb 18 '25	Sale	1.68	8,565	14,347	88,935	Feb 20 05:13 PM
Lenz Robert A.	Head of R&D	Feb 18 '25	Sale	1.67	5,614	9,383	309,092	Feb 20 05:12 PM
Pinto Joshua	President	Feb 18 '25	Sale	1.67	8,048	13,477	76,952	Feb 20 05:11 PM
Suh Carol Y.	Officer	Feb 18 '25	Proposed Sale	1.68	9,540	16,020		Feb 18 05:51 PM
Milligan Michael Lee	Officer	Feb 18 '25	Proposed Sale	1.69	1,978	3,351		Feb 18 05:49 PM
Pinto Joshua	Officer	Feb 18 '25	Proposed Sale	1.67	8,048	13,478		Feb 18 05:45 PM
Lenz Robert A.	Officer	Feb 18 '25	Proposed Sale	1.67	5,614	9,383		Feb 18 05:43 PM
Gosebruch Henry O	Officer	Feb 18 '25	Proposed Sale	1.67	6,857	11,462		Feb 18 05:41 PM
BERNS PAUL L	Officer	Feb 18 '25	Proposed Sale	1.69	13,871	23,468		Feb 18 05:40 PM
Aurora Daljit Singh	Officer	Feb 18 '25	Proposed Sale	1.68	8,565	14,348		Feb 18 05:38 PM
Fust Matthew K	Director	Oct 18 '24	Option Exercise	5.29	14,049	74,309	34,149	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Option Exercise	6.81	7,739	52,730	27,839	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Sale	17.03	14,049	239,319	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Sale	17.01	7,739	131,643	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Proposed Sale	17.03	14,049	239,319		Oct 18 04:01 PM
Fust Matthew K	Director	Oct 17 '24	Proposed Sale	17.01	7,739	131,643		Oct 17 04:26 PM
Lenz Robert A.	Head of R&D	Oct 10 '24	Sale	15.09	8,260	124,603	314,706	Oct 11 04:10 PM
Lenz Robert A.	Head of R&D	Oct 09 '24	Sale	15.01	5,563	83,507	322,966	Oct 11 04:10 PM
Lenz Robert A.	Officer	Oct 10 '24	Proposed Sale	15.09	8,260	124,603		Oct 10 04:30 PM
Lenz Robert A.	Officer	Oct 09 '24	Proposed Sale	15.01	5,563	83,507		Oct 09 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NMRA

Neumora Therapeutics Inc

Upgrade your FINVIZ experience